

and the contents of the substitute computer readable form of the Sequence listing are the same. Please use the CFR Sequence Listing submitted herein and please direct by amendment the entry of this Paper sequence listing into the specification.

**Statement Regarding Sequence Listing Under 37 C.F.R. §1.821(f)**

Applicant submits this statement in compliance with 37 C.F.R. §1.821(f). A "Sequence Listing" (computer readable and paper copies is submitted herewith).

Applicant hereby states that the "Sequence Listing" content of the paper copy and the computer readable copy are the same.

**Statement Regarding Sequence Listing Under 37 C.F.R. §1.821(g)**

Applicant submits this statement in compliance with 37 C.F.R. §1.821(f).

Applicant hereby states that the content of the "Sequence Listing" (computer readable and paper copies submitted herewith) contain no new matter in accordance with 37 CFR 1.821(g).

**Request for Entry into Application**

Applicant requests that the enclosed "Sequence Listing" (amended paper sequence listing and the computer readable form (CRF) sequence listing) be entered into this application.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Dana Rewoldt", is written over a horizontal line.

Dana Rewoldt, Reg. No. 33,762  
Syngenta Biotechnology  
2369 330th Street, Box 500  
Slater, IA 50244  
(515) 685-5201